[Research advances in withdrawal of nucleos(t)ide analogues in chronic hepatitis B patients].
Withdrawal of nucleos(t)ide analogues in chronic hepatitis B patients has always been a clinical problem for scholars and patients. Many studies showed that the withdrawal of nucleos(t)ide analogues often leads to a high recurrence rate in clinical practice. The factors such as age, baseline HBV DNA load, time of drug consolidation therapy, and HBsAg level are associated with recurrence after withdrawal of nucleos(t)ide analogues. In addition, there are many studies on safety after withdrawal of nucleos(t)ide analogues and response to retreatment after recurrence. This article reviews the research advances in the aspects mentioned above.